As a dividend investor, it pays to follow how much of a company's money goes toward funding its dividend. A nice yield now won't matter much if the company can't keep making those payments going forward.

Here, we'll highlight a given company and its closest competitors to see just how safe their dividends are, with a little help from three crucial tools:

  • The interest coverage ratio, or earnings before interest and taxes, divided by interest expense. The interest coverage ratio measures a company's ability to pay the interest on its debt. An interest coverage ratio less than 1.5 is questionable; a number less than 1 means that the company is not bringing in enough money to cover its interest expenses.
  • The EPS payout ratio, or dividends per share divided by earnings per share. The EPS payout ratio measures the percentage of earnings that go toward paying the dividend. A ratio greater than 80% is worrisome.
  • The FCF payout ratio, or dividends per share divided by free cash flow per share. Earnings alone don't always paint a complete picture of a business' health. The FCF payout ratio measures the percent of free cash flow devoted toward paying the dividend. Again, a ratio greater 80% could be a red flag.

Let's examine Teva Pharmaceutical (Nasdaq: TEVA) and three of its peers.

Company

Yield

Interest Coverage

EPS Payout Ratio

FCF Payout Ratio

Teva

2.0%

15.3

22.1%

34.0%

AstraZeneca (NYSE: AZN)

5.2%

29.2

44.6%

43.0%

Johnson & Johnson (NYSE: JNJ)

3.4%

34.7

49.0%

59.9%

Bristol-Myers Squibb (NYSE: BMY)

4.7%

44.7

67.4%

51.2%

Source: Capital IQ, a division of Standard & Poor's.

With an interest coverage of 15.3, Teva covers every $1 in interest expenses with $15 in operating earnings. Given that its EPS payout ratio and FCF payout ratio are below 35%, you shouldn't have to worry that Teva will need to cut its dividend anytime soon. The company has been doing well, but some are worried about its cash conversion cycle.

Another tool for better investing
Most investors don't keep tabs on their companies. That's a mistake. If you take the time to read past the headlines and crack a filing now and then, you're in a much better position to spot potential trouble early. We can help you keep tabs on your companies with My Watchlist, our free, personalized stock-tracking service.

Follow Dan Dzombak on Twitter at @DanDzombak to check out his musings and see what articles he finds interesting. The Motley Fool owns shares of Teva Pharmaceutical Industries and Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and Teva Pharmaceutical Industries, along with creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.